Gen­mab and BioN­Tech to col­lab­o­rate on new can­cer can­di­date; Small Aus­tralian biotech sees hope in brain metas­tases tri­al

Two Eu­ro­pean biotechs are up­ping the ante on their col­lab­o­ra­tion.

Gen­mab and BioN­Tech will ex­pand their re­la­tion­ship to de­vel­op and po­ten­tial­ly com­mer­cial­ize new im­munother­a­pies for the treat­ment of can­cer. The com­pa­nies will work joint­ly on re­search, de­vel­op­ment and then com­mer­cial­iza­tion of the mono­spe­cif­ic an­ti­body can­di­dates for var­i­ous can­cer in­di­ca­tions.

The duo came to­geth­er well be­fore BioN­Tech be­came a house­hold name be­cause of its Covid-19 mR­NA vac­cine with Pfiz­er. Gen­mab and its Ger­man part­ner start­ed the joint de­vel­op­ment of bis­pe­cif­ic can­cer an­ti­bod­ies in 2015.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER